📊 NSPR Key Takeaways
Is InspireMD, Inc. (NSPR) a Good Investment?
InspireMD demonstrates early market traction with 28.1% YoY revenue growth in the medical device sector, but faces critical fundamental challenges: operating losses of -$14M on only $3.4M revenue, negative operating cash flow of -$12.3M annually, and insufficient cash runway (11.4M cash = <12 months at current burn rate). The company requires major capital raises or dramatic operational improvements to achieve viability.
Top-line growth is improving, but the business remains far from profitability with operating and net margins worse than -500% and ROE/ROA deeply negative. Cash burn is severe relative to the $8.94M cash balance, implying a short runway and likely need for external financing despite low leverage and strong current ratios. Until gross margin expands materially and operating expenses are contained, fundamentals remain unattractive.
InspireMD, Inc. Key Strengths (NSPR)
- Positive 28.1% YoY revenue growth indicates market validation and product demand
- Conservative balance sheet with low leverage (0.11x Debt/Equity) and strong liquidity ratios (5.15x current ratio)
- Medical device sector with structural potential for higher margins and pricing power at scale
- Strong liquidity (current 5.74x, quick 5.42x)
- Low leverage (Debt/Equity 0.09x)
- Solid revenue growth (+28.1% YoY)
NSPR Stock Risks: InspireMD, Inc. Investment Risks
- Severe cash burn: -$12.3M operating cash flow with only $11.4M cash on hand (less than 12 months runway at current rate)
- Extreme unprofitability: -411% operating margin and -403% net margin on minimal revenue base
- Weak 20.2% gross margin for medtech suggests fundamental cost structure or operational issues
- No insider trading activity in 90 days may signal lack of confidence in near-term turnaround
- Pre-profitable early-stage company with high execution risk and likely significant shareholder dilution from future capital raises
- Extreme unprofitability (operating margin -552.6%, ROE -88.4%)
- High cash burn vs cash ($-36.77M FCF vs $8.94M cash)
- Potential dilution/financing need given negative interest coverage
Key Metrics to Watch
- Monthly/quarterly operating cash burn rate and months of cash runway remaining
- Gross margin expansion trajectory and operating expense reduction initiatives
- Quarterly revenue growth sustainability and timeline to positive operating cash flow
- Operating cash flow (quarterly)
- Gross margin trend
InspireMD, Inc. (NSPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.15x current ratio provides a solid financial cushion.
NSPR Profit Margin, ROE & Profitability Analysis
NSPR vs Healthcare Sector: How InspireMD, Inc. Compares
How InspireMD, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is InspireMD, Inc. Stock Overvalued? NSPR Valuation Analysis 2026
Based on fundamental analysis, InspireMD, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
InspireMD, Inc. Balance Sheet: NSPR Debt, Cash & Liquidity
NSPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: InspireMD, Inc.'s revenue has grown significantly by 100% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.76 indicates the company is currently unprofitable.
NSPR Revenue Growth, EPS Growth & YoY Performance
NSPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | -$11.2M | $-0.16 |
| Q3 2025 | $1.8M | -$7.9M | $-0.16 |
| Q2 2025 | $1.7M | -$7.9M | $-0.22 |
| Q1 2025 | $1.5M | -$7.0M | $-0.21 |
| Q3 2024 | $1.6M | -$5.2M | $-0.15 |
| Q2 2024 | $1.6M | -$5.1M | $-0.22 |
| Q1 2024 | $1.2M | -$4.3M | $-0.21 |
| Q3 2023 | $1.4M | -$4.5M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
InspireMD, Inc. Dividends, Buybacks & Capital Allocation
NSPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for InspireMD, Inc. (CIK: 0001433607)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NSPR
What is the AI rating for NSPR?
InspireMD, Inc. (NSPR) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NSPR's key strengths?
Claude: Positive 28.1% YoY revenue growth indicates market validation and product demand. Conservative balance sheet with low leverage (0.11x Debt/Equity) and strong liquidity ratios (5.15x current ratio). ChatGPT: Strong liquidity (current 5.74x, quick 5.42x). Low leverage (Debt/Equity 0.09x).
What are the risks of investing in NSPR?
Claude: Severe cash burn: -$12.3M operating cash flow with only $11.4M cash on hand (less than 12 months runway at current rate). Extreme unprofitability: -411% operating margin and -403% net margin on minimal revenue base. ChatGPT: Extreme unprofitability (operating margin -552.6%, ROE -88.4%). High cash burn vs cash ($-36.77M FCF vs $8.94M cash).
What is NSPR's revenue and growth?
InspireMD, Inc. reported revenue of $3.4M.
Does NSPR pay dividends?
InspireMD, Inc. does not currently pay dividends.
Where can I find NSPR SEC filings?
Official SEC filings for InspireMD, Inc. (CIK: 0001433607) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NSPR's EPS?
InspireMD, Inc. has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NSPR's fundamental grade?
Based on our AI fundamental analysis in June 2026, InspireMD, Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NSPR stock overvalued or undervalued?
Valuation metrics for NSPR: ROE of -31.4% (sector avg: 15%), net margin of -402.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NSPR's AI grade for 2026?
Our dual AI analysis gives InspireMD, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NSPR's free cash flow?
InspireMD, Inc.'s operating cash flow is $-12.3M, with capital expenditures of $194.0K. FCF margin is -368.8%.
How does NSPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -402.9% (avg: 12%), ROE -31.4% (avg: 15%), current ratio 5.15 (avg: 2).